Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

Related Citations for PubMed (Select 16227633)

1.

Prognostic factors in patients with colorectal cancer receiving adjuvant chemotherapy or chemoradiotherapy: a pooled analysis of two randomized studies.

Bamias A, Basdanis G, Xanthakis I, Pavlidis N, Fountzilas G.

Int J Gastrointest Cancer. 2005;36(1):29-38.

PMID:
16227633
2.

Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.

Fountzilas G, Zisiadis A, Dafni U, Konstantaras C, Hatzitheoharis G, Papavramidis S, Bousoulegas A, Basdanis G, Giannoulis E, Dokmetzioglou J, Katsohis C, Nenopoulou E, Karvounis N, Briassoulis E, Aravantinos G, Kosmidis P, Skarlos D, Pavlidis N.

Oncology. 2000 Apr;58(3):227-36.

PMID:
10765125
3.

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM.

J Clin Oncol. 2004 May 15;22(10):1797-806. Epub 2004 Apr 5.

4.

Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.

Wolmark N, Bryant J, Smith R, Grem J, Allegra C, Hyams D, Atkins J, Dimitrov N, Oishi R, Prager D, Fehrenbacher L, Romond E, Colangelo L, Fisher B.

J Natl Cancer Inst. 1998 Dec 2;90(23):1810-6.

5.

Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.

Hotta T, Takifuji K, Arii K, Yokoyama S, Matsuda K, Higashiguchi T, Tominaga T, Oku Y, Yamaue H.

Anticancer Res. 2006 Mar-Apr;26(2B):1425-32.

6.

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ.

J Clin Oncol. 2007 Aug 10;25(23):3456-61.

7.

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.

Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM.

J Clin Oncol. 2004 May 15;22(10):1785-96. Epub 2004 Apr 5.

8.

Adjuvant systemic therapies in patients with colorectal cancer: an audit on clinical practice in Italy.

Drug Utilization Review Team in Oncology.

Tumori. 2005 Nov-Dec;91(6):472-6.

PMID:
16457144
9.

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U; Eastern Cooperative Oncology Group.

Clin Cancer Res. 2004 Mar 1;10(5):1670-7.

10.

A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.

Koda K, Miyazaki M, Sarashina H, Suwa T, Saito N, Suzuki M, Ogawa K, Watanabe S, Kodaira S, Nakazato H.

Int J Oncol. 2003 Jul;23(1):165-72.

PMID:
12792790
11.

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.

Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.

Oncology. 2006;70(5):366-77. Epub 2006 Dec 15.

PMID:
17179731
12.

Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.

Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG.

J Clin Oncol. 2005 Dec 1;23(34):8706-12.

13.

Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.

Sahajpal A, Vollmer CM Jr, Dixon E, Chan EK, Wei A, Cattral MS, Taylor BR, Grant DR, Greig PD, Gallinger S.

J Surg Oncol. 2007 Jan 1;95(1):22-7.

PMID:
17066435
14.

Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.

Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB 3rd, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS Jr, Leichman CG, Macdonald JS.

J Clin Oncol. 2006 Aug 1;24(22):3542-7.

15.

Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.

Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, Beretta GD, Catalano V, Bertetto O, Barni S, Frontini L, Aitini E, Rota S, Torri V, Floriani I; Italian Group for the Study of Digestive Tract Cancer, Pozzo C, Rimassa L, Mosconi S, Giordani P, Ardizzoia A, Foa P, Rabbi C, Chiara S, Gasparini G, Nardi M, Mansutti M, Arnoldi E, Piazza E, Cortesi E, Pucci F, Silva RR, Sobrero A, Ravaioli A.

J Natl Cancer Inst. 2007 Apr 18;99(8):601-7.

16.

lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy.

Kim YS, Kim JH, Yoon SM, Choi EK, Ahn SD, Lee SW, Kim JC, Yu CS, Kim HC, Kim TW, Chang HM.

Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):796-802. doi: 10.1016/j.ijrobp.2008.08.065. Epub 2009 Mar 14.

PMID:
19289261
17.

Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.

Miller RC, Iott MJ, Corsini MM.

Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):364-8. doi: 10.1016/j.ijrobp.2008.11.069. Review.

PMID:
19735864
18.

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.

Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P; Meta-Analysis Group in Cancer.

J Clin Oncol. 2004 Sep 15;22(18):3766-75. Erratum in: J Clin Oncol. 2005 Feb 20;23(6):1337-8.

19.

Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin.

de la Torre A, García-Berrocal MI, Arias F, Mariño A, Valcárcel F, Magallón R, Regueiro CA, Romero J, Zapata I, de la Fuente C, Fernández-Lizarbe E, Vergara G, Belinchón B, Veiras M, Molerón R, Millán I.

Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):102-10. Epub 2007 Sep 14.

PMID:
17869446
20.

Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.

Angitapalli R, Litwin AM, Kumar PR, Nasser E, Lombardo J, Mashtare T, Wilding GE, Fakih MG.

Oncology. 2009;76(5):363-8. doi: 10.1159/000210025. Epub 2009 Mar 25.

PMID:
19321964
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk